Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis

Journal of Cellular Biochemistry

Volumn 114, Issue 6, 2013, Pages 1217-1222

  Sugatani, Toshifumi ^a   Hruska, Keith A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; FasL; miR 21; Osteoclast

Indexed keywords

ESTROGEN; FAS LIGAND; MICRORNA 21;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HORMONE ACTION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FAS LIGAND PROTEIN; GENE EXPRESSION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; OSTEOCLASTS; RANK LIGAND;

EID: 84876261835     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24471     Document Type: Article

References (17)

1. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X,. 1999. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290.
2. Bushati N, Cohen SM,. 2007. MicroRNA functions. Annu Rev Cell Dev Biol 23: 175-205.
3. Fujiyama-Nakamura S, Yamagata K, Kato S,. 2010. Hormonal repression of miRNA biosynthesis through a nuclear steroid hormone receptor. Adv Exp Med Biol 700: 43-55.
4. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF,. 1994. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
5. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN,. 2010. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18: 282-293.
6. Khosla S, Oursler MJ, Monroe DG,. 2012. Estrogen and the skeleton. Trends Endocrinol Metab 23: 576-581.
7. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M,. 2008. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27: 535-545.
8. Lian JB, Stein GS, van Wijnen AJ, Stein JL, Hassan MQ, Gaur T, Zhang Y,. 2012. MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol 8: 212-227.
9. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC,. 2010. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 24: 323-334.
10. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S,. 2007. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130: 811-823.
11. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN,. 2010. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 120: 3912-3916.
12. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, Abdellatif M,. 2010. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 285: 20281-20290.
13. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R,. 2001. Estrogen decreases osteoclast formation by down-regulating receptor activator of NFkappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276: 8836-8840.
14. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N,. 1995. Modulation of osteoclast differentiation by local factors. Bone 17: 87S-91S.
15. Sugatani T, Hruska KA,. 2009. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem 284: 4667-4678.
16. Sugatani T, Vacher J, Hruska KA,. 2011. A microRNA expression signature of osteoclastogenesis. Blood 117: 3648-3657.
17. Tanaka S, Nakamura K, Takahasi N, Suda T,. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208: 30-49.